Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Ophthalmic Emulsion
Emulsion · 1 trial · 5 indications
| Name | Type | Description |
|---|---|---|
| Ophthalmic Emulsion | DRUG | - |
* Eighteen years or older * Diagnosis of moderate to severe dry eyes for at least 6 months and meet one or all of the following criteria: * Diagnosis of autoimmune disorder * Female 65 years of age or older
Emulsion is an investigational small molecule being studied for keratoconjunctivitis sicca, also known as dry eye syndrome. It was evaluated in a Phase 3 clinical trial in patients with moderate or severe dry eye syndrome. Emulsion has not been approved by the FDA and remains in clinical development.
Emulsion is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating Emulsion in keratoconjunctivitis sicca and related autoimmune conditions.
Emulsion is in Phase 3 clinical development. One Phase 3 trial has been completed, and no active trials are currently listed. The completed study enrolled 290 participants with moderate or severe dry eye syndrome. Emulsion is investigational and has not received FDA approval.
Emulsion has been studied in one completed Phase 3 trial, NCT00025818, titled "Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome." The randomized, double-blind study enrolled 290 participants aged 18 years and older in the United States.
Yes, Emulsion is also known as Ophthalmic Emulsion. Both names refer to the same investigational small molecule developed by AbbVie Inc. for keratoconjunctivitis sicca. The alternative name reflects its ophthalmic formulation and route of administration.
The Phase 3 trial of Emulsion, NCT00025818, studied patients with moderate or severe dry eye syndrome. Enrolled participants also had related conditions including keratoconjunctivitis sicca, Sjogren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, and systemic scleroderma.